drugset / Trial / NCT05798156
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Phase 2
Active not recruiting
125 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Arbeitsgemeinschaft medikamentoese Tumortherapie · collabCharite University, Berlin, Germany · collabHoffmann-La Roche · collabRoche Pharma AG · collabUniversity of Salzburg · collabZentrum für Klinische Studien Leipzig · collab
NaSingle-groupOpen-labelTreatment
Summary
In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The outcome and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2025-04-12
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | — |
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |